Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press97010.17650/1994-4098-2022-18-2-60-66MAMMOLOGY. REVIEWSМАММОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИEffectiveness of mammography screening for women aged 40–49Систематический обзор эффективности маммографического скрининга для женщин в возрасте 40–49 летBelayaYu. A.БелаяЮ. А.
Russian Federation

40 Kalinina St., Khanty-Mansiysk 628002

628002 Ханты-Мансийск, ул. Калинина, 40

juliyabelaya86@gmail.comDistrict Clinical HospitalБУ «Окружная клиническая больница»1909202218260661609202216092022https://ojrs.abvpress.ru/ojrs/article/view/970

The aim of the work was to review randomized controlled trials regarding the efficacy of screening mammography in women aged 40–49 years.

Google Scholar and PubMed databases were searched for English-language publications for randomized controlled trials. Inclusion criteria were studies evaluating the possible benefit/harm of mammographic screening in women 40–49 years old, a follow-up period of at least 10 years, primary breast cancer, regarding as primary outcomes reduction of breast cancer mortality, and side effects screening mammography.

A search for the specified keywords found 2453 sources in electronic databases, of which only 83 studies were published as articles. After analyzing these studies, only 5 studies met the inclusion criteria. An analysis of these studies according to the inclusion criteria is subsequently presented in the article.

Based on the available data from randomized trials, no definitive conclusion about the effectiveness of mammographic screening in women 40–49 years of age can yet be drawn. Therefore, it is too early to draw a line in the debate about the appropriateness of mammography in the 40–49 age group.

Целью настоящей работы является обзор рандомизированных контролируемых исследований, посвященных эффективности скрининговой маммографии у женщин возрастной категории 40–49 лет.

В базах данных Google Scholar и PubMed был реализован поиск англоязычных публикаций результатов рандомизированных контролируемых исследований. Критериями включения служили исследования, оценивающие возможную пользу/вред от маммографического скрининга у женщин 40–49 лет, период наблюдения за женщинами минимум 10 лет, первичный рак молочной железы, в которых в качестве исходов рассматривались сокращение смертности от рака молочной железы, побочные эффекты скрининговой маммографии.

В результате поиска по указанным ключевым словам были найдены 2453 источника в электронных базах данных, из которых только 83 исследования были опубликованы в виде оригинальных статей. После анализа данных исследований только 5 исследований соответствовали критериям включения. Анализ указанных исследований соответственно критериям включения представлен в статье.

На основании имеющихся данных из рандомизированных контролируемых исследований пока невозможно рекомендовать расширение маммографического скрининга для более молодых возрастных групп. Однако дальнейшие исследования с масштабным включением технологий цифровой маммографии, с учетом физиологических особенностей ткани молочной железы у женщин 40–49 лет и молекулярно-биологических характеристик наиболее часто встречающихся опухолей позволят рассмотреть данный вопрос в свете современных технологических возможностей. 

breast cancermammographic screeningwomen 40–49 years oldeffectiveness of screeningharms of screeningрак молочной железымаммографический скринингженщины 40–49 летэффективность скринингавред от скринингаFerlay J., Colombet M., Soerjomataram I. et al. Cancer statistics for the year 2020: An overview. Int J Cancer 2021;149(4):778–89. DOI: 10.1002/ijc.33588.Мешков Д.О., Безмельницына Л.Ю. Организация медицинской помощи при раке молочной железы: динамика за 2009–2019 гг. Вестник Северо-Восточного федерального университета им. М.К. Аммосова 2020;3(20):48–52. DOI: 10.25587/SVfu.2020.20.3.006.Nyström L., Andersson I., Bjurstam N. et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002;359(9310):909–19. DOI: 10.1016/S0140-6736(02)08020-0.Ray K.M., Joe B.N., Freimanis R.I. et al. Screening mammography in women 40-49 years old: current evidence. AJR Am J Roentgenol 2018;210(2):264–70. DOI: 10.2214/AJR.17.18707.Mandrik O., Zielonke N., Meheus F. et al. Systematic reviews as a “lens of evidence”: Determinants of benefits and harms of breast cancer screening. Int J Cancer 2019;145(4):994–1006. DOI: 10.1002/ijc.32211.Andersson I., Janzon L. Reduced breast cancer mortality in women under age 50: updated results from the Malmö Mammographic Screening Program. JNCI Monographs 1997;22:63–7. DOI: 10.1093/jncimono/1997.22.63.Bjurstam N., Björneld L., Warwick J. et al. The Gothenburg Breast Screening Trial. Cancer 2003;97(10):2387–96. DOI: 10.1002/cncr.11361.Shapiro S., Venet W., Strax P. et al. Selection, follow-up, and analysis in the Health Insurance Plan Study: a randomized trial with breast cancer screening. National Cancer Institute Monograph 1985;67:65–74.Tab́r L., Vitak B., Chen T.H. et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology 2011;260(3):658–63. DOI: 10.1148/radiol.11110469.Alexander F.E., Anderson T.J., Brown H.K. et al. 14-years of follow-up from the Edinburgh randomised trial of breastcancer screening. Lancet 1999;353. DOI: 10.1016/S0140-6736(98)07413-3.Miller A.B., To T., Baines C.J., Wall C. The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up: a randomized screening trial of mammography in women age 40 to 49 years. Ann Int Med 2002;137(5 Part 1):305–12. DOI: 10.7326/0003-4819-137-5_Part_1-200209030-00005.Moss S., Wale C., Smith R. et al. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years’ follow-up: a randomised controlled trial. Lancet Oncol 2015;16(9):1123–32. DOI: 10.1016/S1470-2045(15)00128-X.Miller K.D., Nogueira L., Mariotto A.B. et al. Cancer treatment and survivorship statistics, 2019. CA 2019;69(5):363–85. DOI: 10.3322/caac.21565.Duffy S.W, Sasieni P.D. Mammography screening for breast cancer – the UK Age trial – Authors’ reply. Lancet Oncol 2020;21(11):е510. DOI: 10.1016/S1470-2045(20)30627-6.Rachet B., Maringe C., Nur U. et al. Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England. Lancet Oncol 2009;10(4):351–69. DOI: 10.1016/S1470-2045(09)70028-2.Lemasters T., Sambamoorthi U. A national study of out-of-pocketexpenditures for mammography screening. J Women’s Heal 2011;20(12):1775–83. DOI: 10.1089/jwh.2010.2251.Duffy S.W., Vulkan D., Cuckle H. et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. Lancet Oncol 2020;21(9):1165–72. DOI: 10.1016/S1470-2045(20)30398-3.Johns L.E., Moss S.M. False-positive results in the randomized controlled trial of mammographic screening from age 40 (“age” trial). Cancer Epidemiol Biomarkers Prev 2010;19(11):2758–64. DOI: 10.1158/1055-9965.Baines C.J., to T., Miller A.B. Revised estimates of overdiagnosis from the canadian national breast screening study. Prev Med 2016;90:66–71. DOI: 10.1016/j.ypmed.2016.06.033.Narod S.A., Sun P., Wall C. et al. Mammography before age 50 and breast cancer mortality. Curr Oncol 2014;21(5):217–21. DOI: 10.3747/co.21.2067.Moss S.M., Cuckle H., Evans A. et al. Effect of mammographic screening from age 40 years on, Controlled cancer mortality at 10 years follow-up: a randomized, trial. Lancet 2006;368:2053. DOI: 10.1016/S0140-6736(06)69834-6.Johns L.E., Moss S.M. ATMGF results in the randomized controlled trial of mammographic screening from age 40 (“age” trial). CEBP 2010;19:2758–64. DOI: 10.1258/jms.2010.009091.Evans A.J., Kutt E., Record C. et al. Radiological and pathological findings of interval cancers in a multi-centre, randomized, controlled trial of mammographic screening in women from age 40–41 years. Clinical Rad 2007;62(4):348–52. DOI: 10.1016/j.crad.2006.10.010.Kingston N., Thomas I., Johns L. et al. Assessing the amount of unscheduled screening (“сontamination”) in the control arm of the UK “age” trial. Cancer Epid Prev Biomarkers 2010;19(4):1132–6. DOI: 10.1158/1055-9965.EPI-09-0996.Moss S., Waller M., Anderson T.J., Cuckle H. Randomised controlled trial of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Brit J Cancer 2005;92(5):955–60. DOI: 10.1038/sj.bjc.6602395.Moss S. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. J Med Screening 1999;6(3):144–8. DOI: 10.1136/jms.6.3.144.Moss S.M., Cuckle H., Evans A. et al. Effect of mammographic screening from age 40 on breast cancer mortality at 10 years’ follow-up: a randomized controlled trial. Obstetr Gynecol Survey 2007;62(5):314, 315. DOI: 10.1016/S0140-6736(06)69834-6.Van den Ende C., Oordt-Speets A.M., Vroling H. et al. Benefits and harms of breast cancer screening with mammography in women aged 40–49 years: A systematic review. Int J Cancer 2017;141(7):1295–306. DOI: 10.1002/ijc.30794.Miller A.B. Final results of the UK Age trial on breast cancer screening age. Lancet Oncol 2020;21(9):1125, 1126. DOI: 10.1016/S1470-2045(20)30428-9.Narod S.A. Reflections on screening mammography and the early detection of breast cancer. Curr Oncol 2014;21(5):210–4. DOI: 10.3747/co.21.2068.Johns L.E., Moss S.M., Trial Management Group. Randomized controlled trial of mammographic screening from age 40 (“age” trial): patterns of screening attendance. J Med Screening 2010;17(1):37–43. DOI: 10.1258/jms.2010.009091.Wallis M., Neilson F., Hogarth H. et al. Cumulative attendance assessment and cancer detectionrate over four screening rounds in five E programmes: a retrospective study. JPH (Oxf) 2007;29:275–80. DOI: 10.1093/pubmed/fdm020.Lång K., Dustler M., Dahlblom V. et al. Identifying normal mammograms in a large screening population using artificial intelligence. Eur Radiol 2021;31(3):1687–92. DOI: 10.1007/s00330-020-07165-1.Schünemann H.J., Lerda D., Quinn C. et al. Breast cancer screening and diagnosis: A synopsis of the european breast guidelines. Ann Intern Med 2020;172(1):46–56. DOI: 10.7326/M19-2125.